Clinical trial · Interventional
The RCT of Acupuncture on PCOS Combined With IR
The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial
NCT02491333CI-TRIAL-00057241completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objectives of this randomized controlled trial are to compare insulin sensitivity following true acupuncture + placebo metformin (Group 1) vs sham acupuncture + placebo metformin (Group 2) vs sham acupuncture + metformin (Group 3) in women with PCOS and IR.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Insulin Resistance | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| metformin | Drug | Metformin | ALIAS |
| Placebo metformin | Drug | — | UNRESOLVED |
| sham acupuncture | Other | — | UNRESOLVED |
| true acupuncture | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- true acupuncture + placebo metformin
- description
- True acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception. True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
- interventionNames
- Other: true acupuncture
- Drug: Placebo metformin
- type
- SHAM_COMPARATOR
- label
- sham acupuncture + placebo metformin
- description
- Sham acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception. Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placement of needles is unlikely to affect ovulation and IR in women with PCOS. Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria:
1. Chinese women aged from 18 to 40 years.
2. BMI ≥18.5kg/m2.
3. Confirmed diagnosis of PCOS according to modified Rotterdam criteria in 2003 including at least two of the following three features: ①Oligo-(an intermenstrual interval \>35 days or \<8 cycles in the past year), amenorrhea (an intermenstrual interval\>90 days) and/or; ② polycystic ovarian morphology, i.e. presence of \>12 antral follicles (≤ 9mm) and/or ovarian volume \>10 ml on transvaginal scanning and/or; ③clinical and/or biochemical hyperandrogenism. Clinical hyperandrogenism in China Mainland is defined as a Ferriman-Gallwey (FG) score ≥5 ; biochemical hyperandrogenism is total testosterone (T) \> 2.6 nmol/l and free testosterone ≥6.0 pg/ml.
4. Presence of IR as defined by the homeostatic model assessment (HOMA-IR: \[fasting insulin (μU/mL) × fasting glucose (mmol/L)\] / 22.5). A value ≥ 2.14 will be considered to be indicative of IR.
5. No immediate fertility wish and willingness to use barrier methods to contraception for one year.
6. Willingness to sign the consent form.
Exclusion Criteria:
1. Exclusion of other endocrine disorders:
① Uncorrected thyroid disease (defined as TSH \< 0.2 mIU/mL or \>5.5 mIU/mL). A normal level within the last year is adequate for entry.
② Poorly controlled of Type I or Type II diabetes (defined as a HbA1c level \> 7.0%), or patients receiving antidiabetic medications such as insulin, thiazolidinediones, acarbose, or sulfonylureas likely to confound the effects of study medication; Patients currently receiving metformin XR (extended release) for a diagnosis of Type I or Type II diabetes or for PCOS are alsoexcluded.
* Cushing's syndrome (define as an archetype of MetS. High glucocorticoid levels lead to muscle, liver and adipocyte insulin resistance. 17-OHCS\>55umol/24h or UFC\>304nmol/24h) ④ Congenital adrenal hyperplasia (define as patients with known 21-hydroxylase deficiency or other enzyme deficiency leading to the phenotype of congenital adrenal hyperplasia. 17-OHP\>10 ng/ml in ACTH 1-24 h excited test (after 60 min)) ⑤ Suspected androgen secreting adrenal or ovarian tumor.
2. Use of hormonal or other medication including Chinese Herbal prescriptions which may affect the outcome the last 2 months.
3. Receiving acupuncture in the past 2 months.
4. Within 6 weeks pregnancy.
5. Post-abortion or postpartum within the past 6 weeks.
6. Breastfeeding within the last 4 months.
7. Not willing to give written consent to the study.
8. Having a bariatric surgery procedure within the past 12 months or being in a period of acute weight loss.
9. Additional exclusion criteria including:
* Patients on oral contraceptives, depot progestins, or hormonal implants (including Implanon). A two month washout period will be required prior to screening for patients on these agents. Longer washouts may be necessary for certain depot contraceptive forms or implants, especially where the implants are still in place. A one-month washout will be required for patients on oral cyclic progestins.
* Heart disease ③ Patients with a history of, or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma.
* Patients enrolled into other studies that require medications. ⑤ Patients taking longer than a one month break during the protocol should not be enrolled.References
Publications (39)
- BACKGROUNDLakkakula BV, Thangavelu M, Godla UR. Genetic variants associated with insulin signaling and glucose homeostasis in the pathogenesis of insulin resistance in polycystic ovary syndrome: a systematic review. J Assist Reprod Genet. 2013 Jul;30(7):883-95. doi: 10.1007/s10815-013-0030-1. Epub 2013 Jun 22. PMID 23794114
- BACKGROUNDNestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol. 1997 May;15(2):111-22. doi: 10.1055/s-2007-1016294. PMID 9165656
- BACKGROUNDFarrell K, Antoni MH. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril. 2010 Oct;94(5):1565-74. doi: 10.1016/j.fertnstert.2010.03.081. Epub 2010 May 14. PMID 20471009
- BACKGROUNDBhathena RK. Insulin resistance and the long-term consequences of polycystic ovary syndrome. J Obstet Gynaecol. 2011;31(2):105-10. doi: 10.3109/01443615.2010.539722. PMID 21281021
- BACKGROUNDHernandez-Valencia M, Hernandez-Rosas M, Zarate A. [Care of insulin resistance in polycystic ovary syndrome]. Ginecol Obstet Mex. 2010 Nov;78(11):612-6. Spanish. PMID 21298999
- BACKGROUNDFranks S. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin Endocrinol (Oxf). 2011 Feb;74(2):148-51. doi: 10.1111/j.1365-2265.2010.03934.x. PMID 21121941
- BACKGROUNDPauli JM, Raja-Khan N, Wu X, Legro RS. Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med. 2011 Dec;28(12):1445-54. doi: 10.1111/j.1464-5491.2011.03460.x. PMID 21950959
- BACKGROUNDZhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74. doi: 10.1172/JCI13505.